

**INDOCO REMEDIES LIMITED**

Regd. Office : Indoco House, 166, CST Road, Santacruz (E), Mumbai 400 098

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2009**

(Rs. In Lacs)

Sr.No	Particulars	Quarter ended 30.09.2009 (Unaudited)	Quarter ended 30.09.2008 (Unaudited)	Half Year ended 30.09.2009 (Unaudited)	Half Year ended 30.09.2008 (Unaudited)	Year ended 31.03.2009 (Audited)
1	<b>(a) Sales and Income from Operations</b>	<b>9,630</b>	7,968	<b>19,555</b>	19,058	<b>35,526</b>
	Less : Excise Duty	87	106	178	247	462
	<b>Net Sales and Income from Operations</b>	<b>9,543</b>	7,862	<b>19,377</b>	18,811	<b>35,064</b>
	<b>(b) Other Operating income</b>	<b>70</b>	72	<b>299</b>	136	<b>338</b>
	<b>Total</b>	<b>9,613</b>	7,934	<b>19,676</b>	18,947	<b>35,402</b>
2	<b>Expenditure :</b>					
	(a) (Increase)/Decrease in Finished Goods, Stock in Trade and Work in Progress	196	(61)	(74)	(416)	(513)
	(b) Consumption of raw materials	3,327	2,752	6,990	6,506	12,376
	(c) Purchase of traded goods	556	673	1,193	1,803	3,094
	(d) Employees cost	1,446	1,215	2,740	2,338	4,794
	(e) Depreciation	289	252	568	536	1,116
	(f) Research & Development Expenses	225	229	473	434	923
	(g) Other Expenditure	2,555	2,471	4,954	4,737	9,768
	(h) Total	8,594	7,531	16,844	15,938	31,558
3	<b>Profit from Operations before Interest and Exceptional Items</b>	<b>1,019</b>	403	<b>2,832</b>	3,009	<b>3,844</b>
4	Other Income	6	26	14	48	55
5	<b>Profit before Interest and Exceptional Items</b>	<b>1,025</b>	429	<b>2,846</b>	3,057	<b>3,899</b>
6	Interest	66	146	159	282	585
7	<b>Profit after Interest but before Exceptional Items</b>	<b>959</b>	283	<b>2,687</b>	2,775	<b>3,314</b>
8	Exceptional Items	-	-	-	-	-
9	<b>Profit from Ordinary Activities before tax</b>	<b>959</b>	283	<b>2,687</b>	2,775	<b>3,314</b>
10	Provision for Tax - Current	259	30	454	309	370
	- Deferred	34	40	74	78	108
	- Fringe Benefit Tax	-	26	-	51	93
	- Prior Year	-	-	-	(31)	(31)
	- MAT Credit	(259)	(30)	(454)	(309)	(370)
11	<b>Net Profit from Ordinary Activities after tax</b>	<b>925</b>	217	<b>2,613</b>	2,677	<b>3,144</b>
12	Extraordinary Items	-	-	-	-	-
13	<b>Net Profit for the period</b>	<b>925</b>	217	<b>2,613</b>	2,677	<b>3,144</b>
14	Paid up Equity Share Capital (Face value Rs.10/- each)	1,228.67	1228.67	1228.67	1228.67	1,228.67
15	Reserves excluding Revaluation Reserves	-	-	-	-	26,616
16	<b>Earning Per Share (EPS) - Not Annualised - Rs.</b>					
	(a) Basic and diluted EPS before Extraordinary Items	7.53	1.77	21.27	21.79	25.59
	(b) Basic and diluted EPS after Extraordinary Items	7.53	1.77	21.27	21.79	25.59
17	Public shareholding					
	- No of Shares	47,97,836	48,48,291	47,97,836	48,48,291	50,29,231
	- % of Shareholding	39.05	39.45	39.05	39.45	40.93
18	Promoters and Promoter Group shareholding					
	<b>a) Pledged/Encumbered</b>					
	- Number of shares	8,200	-	8,200	-	8,200
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter Group)	0.11	-	0.11	-	0.11
	- Percentage of shares (as a % of the total share capital of the company)	0.07	-	0.07	-	0.07
	<b>b) Non-encumbered</b>					
	- Number of shares	74,80,678	-	74,80,678	-	72,49,283
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter Group)	99.89	-	99.89	-	99.89
	- Percentage of shares (as a % of the total share capital of the company)	60.88	-	60.88	-	59.00

## Notes :

- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- The figures for the previous periods have been regrouped and reclassified, wherever necessary.
- Summary of investor complaints : As on 01.07.2009 : Nil, Received during quarter : 2, Resolved: 2, Pending as on 30.09.2009 : Nil.
- The above results have been reviewed by the Audit Committee and taken on record at the meeting of Board of Directors held on 30th October, 2009. The results have been subjected to a Limited Review by the Statutory Auditors of the Company

By Order of the Board

 Place : Mumbai  
 Date : October 30, 2009

**Suresh G. Kare**  
 Chairman & Managing Director